Intelligence / Healthtech / New Clinical Trials / Exir Gene Pharmed
Clinicaltrial registered29 Oct 2026
Exir Gene Pharmed
29 Oct 2026: Trial registered · SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 29 Oct 2026
- Title
- SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE)
- Conditions
- Spinal Muscular Atrophy (SMA)
- Phase
- Early Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Iran
- Country
- Iran
- Reference
- NCT07903376
- Location
- Iran
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Exir Gene Pharmed
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Iran
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.